美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Palvella Therapeutics

151.43

+0.21000.14%

盤前：152.300.8700+0.57%07:48 EDT

成交量：20.20萬

成交額：3,078.80萬

市值：21.82億

市盈率：-30.92

高：155.18

開：152.54

低：150.76

收：151.22

52周最高：161.38

52周最低：54.48

股本：1,440.84萬

流通股本：839.81萬

量比：0.99

換手率：2.40%

股息：- -

股息率：- -

每股收益(TTM):-4.8978

每股收益(LYR):-3.7076

淨資產收益率：-46.63%

總資產收益率：-22.05%

市淨率：10.06

市盈率(LYR):-40.84

資料載入中...

總覽公司新聞資訊公告

Palvella Therapeutics任命全國知名兒科皮膚科專家James R. Treat博士為首席醫療官

Palvella Therapeutics完成向FDA滾動提交Qtorin™雷帕黴素新藥申請，用於治療微囊性淋巴管畸形

Palvella Therapeutics加速美國上市籌備，Qtorin雷帕黴素若獲批有望於2027年上半年啓動

Palvella Therapeutics任命罕見病生物技術資深高管兼商業領袖Matt Pauls加入董事會

Palvella Therapeutics向FDA滾動提交Qtorin™雷帕黴素治療微囊型淋巴管畸形新藥申請的首個模塊

FDA批准對Palvella公司Qtorin™雷帕黴素新藥申請進行滾動審評，用於治療微囊性淋巴管畸形

Palvella Therapeutics宣佈完成Qtorin™雷帕黴素治療微囊型淋巴管畸形的新藥申請前會議

Palvella Therapeutics公布Qtorin™ Rapamycin治療皮膚靜脈畸形II期Toiva試驗新數據，亮相第83屆皮膚病研究學會年會

Palvella Therapeutics宣佈首位患者接受快速通道藥物Qtorin™雷帕黴素治療臨床顯著性血管角化瘤的二期Lotu試驗

Palvella Therapeutics任命罕見皮膚病領域權威皮膚科醫生John D. Doux博士加入董事會

異動解讀 | Palvella Therapeutics新藥申請進展順利，盤中大漲9.42%

Palvella公司Qtorin Rapamycin治療微囊性淋巴管畸形的新藥申請按計劃將於2026年下半年提交

Palvella Therapeutics將於2026年3月31日召開2025財年全年業績電話會議並公布公司最新進展

Palvella Therapeutics任命罕見病商業領袖Jennifer J. Mcdonough為市場準入與患者服務高級副總裁，強化領導團隊

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hant/stock/PVLA/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PVLA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PVLA\",,,,,undefined,":{"symbol":"PVLA","market":"US","secType":"STK","nameCN":"Palvella Therapeutics","latestPrice":151.43,"timestamp":1789588800000,"preClose":151.22,"halted":0,"volume":201973,"hourTrading":{"tag":"盘前","latestPrice":152.3,"preClose":151.43,"latestTime":"07:48 EDT","volume":214,"amount":32399.445920000002,"timestamp":1789645697542,"change":0.87,"changeRate":0.005745,"amplitude":0.015915},"delay":0,"changeRate":0.0013887051977252212,"floatShares":8398100,"shares":14408407,"eps":-4.897784,"marketStatus":"盤前交易","change":0.21,"latestTime":"09-17 08:13:33 EDT","open":152.54,"high":155.18,"low":150.755,"amount":30787964.30692,"amplitude":0.029262,"askPrice":154.2,"askSize":1,"bidPrice":144.21,"bidSize":6,"shortable":3,"etf":0,"ttmEps":-4.897784,"tradingStatus":1,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1789651800000},"marketStatusCode":1,"adr":0,"listingDate":1435636800000,"exchange":"NASDAQ","adjPreClose":151.43,"preHourTrading":{"tag":"盘前","latestPrice":152.3,"preClose":151.43,"latestTime":"07:48 EDT","volume":214,"amount":32399.445920000002,"timestamp":1789645697542,"change":0.87,"changeRate":0.005745,"amplitude":0.015915},"postHourTrading":{"tag":"盘后","latestPrice":151.42,"preClose":151.43,"latestTime":"19:30 EDT","volume":5183,"amount":785506.43,"timestamp":1789601403937,"change":-0.01,"changeRate":-0.000066,"amplitude":0.000066},"volumeRatio":0.99247583101442,"impliedVol":0.4909,"impliedVolPercentile":0.044},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PVLA\",,,,,undefined,":{"symbol":"PVLA","floatShares":8398100,"roa":"-22.05%","roe":"-46.63%","lyrEps":-3.707588,"volumeRatio":0.99247583101442,"shares":14408407,"dividePrice":0,"high":155.18,"amplitude":0.029262,"preClose":151.22,"low":150.755,"week52Low":54.48,"pbRate":"10.06","week52High":161.38,"institutionHeld":0,"latestPrice":151.43,"committee":0.714286,"eps":-4.897784,"divideRate":0,"volume":201973,"delay":0,"ttmEps":-4.897784,"open":152.54,"prevYearClose":104.67,"prevWeekClose":150.13,"prevMonthClose":152.59,"prevQuarterClose":152.82,"fiveDayClose":151.34,"twentyDayClose":150.42,"sixtyDayClose":118.84},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PVLA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-04","symbol":"PVLA","fiscalQuarterEnding":"2026/06","expectedEps":-1.16,"name":null,"time":"盤前","type":"earning","dateTimestamp":1785816000000,"reportTimeType":"pre","actualEps":-1.52},{"market":"US","date":"2026-05-07","symbol":"PVLA","fiscalQuarterEnding":"2026/03","expectedEps":-0.9,"name":null,"time":"盤前","type":"earning","dateTimestamp":1778126400000,"reportTimeType":"pre","actualEps":-1.2},{"market":"US","date":"2026-03-31","symbol":"PVLA","fiscalQuarterEnding":"2025/12","expectedEps":-0.95,"name":null,"time":"盤前","type":"earning","dateTimestamp":1774929600000,"reportTimeType":"pre","actualEps":-1.08},{"market":"US","date":"2025-11-11","symbol":"PVLA","fiscalQuarterEnding":"2025/09","expectedEps":-0.85,"name":null,"time":"盤前","type":"earning","dateTimestamp":1762837200000,"reportTimeType":"pre","actualEps":-1.03},{"market":"US","date":"2025-08-14","symbol":"PVLA","fiscalQuarterEnding":"2025/06","expectedEps":-0.78,"name":null,"time":"盤前","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"pre","actualEps":-0.86}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PVLA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PVLA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.75,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.75,"analysts":16,"updateTime":1778558400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PVLA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PVLA","date":"2026-09-16","current":-30.918064,"percent":0.270642,"low":-60.48704,"twenty":-36.696967,"median":-28.640877,"eighty":-11.134046,"high":46.119317,"avg":-20.179623,"sd":24.180851,"marketCap":2178839306},"quantilePoints":[{"date":"2024-12-20","current":19.163371,"twenty":19.017062,"median":19.163371,"eighty":20.457893,"marketCap":135216749},{"date":"2024-12-27","current":19.083855,"twenty":18.842127,"median":19.083855,"eighty":19.659551,"marketCap":134655684},{"date":"2025-01-03","current":21.071757,"twenty":18.969352,"median":19.083855,"eighty":19.907642,"marketCap":148682317},{"date":"2025-01-10","current":22.216788,"twenty":19.083855,"median":19.083855,"eighty":21.987782,"marketCap":156761658},{"date":"2025-01-17","current":20.960435,"twenty":19.083855,"median":20.523096,"eighty":21.13537,"marketCap":147896826},{"date":"2025-01-24","current":19.863113,"twenty":19.083855,"median":20.650322,"eighty":21.071757,"marketCap":140154124},{"date":"2025-01-31","current":20.674177,"twenty":19.083855,"median":20.658273,"eighty":21.151273,"marketCap":145876991},{"date":"2025-02-07","current":24.729496,"twenty":19.083855,"median":20.674177,"eighty":22.089563,"marketCap":174491323},{"date":"2025-02-14","current":31.090781,"twenty":19.083855,"median":20.912725,"eighty":23.46519,"marketCap":219376551},{"date":"2025-02-21","current":30.565975,"twenty":19.147468,"median":20.992241,"eighty":24.783567,"marketCap":215673520},{"date":"2025-02-28","current":30.804523,"twenty":19.723165,"median":21.111515,"eighty":29.913943,"marketCap":217356716},{"date":"2025-03-07","current":39.042387,"twenty":20.066674,"median":21.469337,"eighty":30.728188,"marketCap":275483086},{"date":"2025-03-14","current":43.678174,"twenty":20.34657,"median":22.439433,"eighty":31.793703,"marketCap":308193196},{"date":"2025-03-21","current":44.751641,"twenty":20.49288,"median":23.46519,"eighty":33.810231,"marketCap":315767578},{"date":"2025-03-28","current":44.688028,"twenty":20.604203,"median":24.292158,"eighty":40.654974,"marketCap":315318726},{"date":"2025-04-04","current":-15.155991,"twenty":19.723165,"median":23.46519,"eighty":39.236406,"marketCap":264229553},{"date":"2025-04-11","current":-13.752893,"twenty":19.083855,"median":22.439433,"eighty":38.266311,"marketCap":239767934},{"date":"2025-04-17","current":-15.396161,"twenty":19.00752,"median":21.77945,"eighty":36.545583,"marketCap":268416676},{"date":"2025-04-25","current":-16.047148,"twenty":-12.608925,"median":21.151273,"eighty":34.239617,"marketCap":279765986},{"date":"2025-05-02","current":-15.493342,"twenty":-14.192783,"median":21.008144,"eighty":33.36176,"marketCap":270110923},{"date":"2025-05-09","current":-14.42287,"twenty":-14.682214,"median":20.912725,"eighty":33.091405,"marketCap":251448313},{"date":"2025-05-16","current":-10.548775,"twenty":-14.614161,"median":20.674177,"eighty":32.251716,"marketCap":243497378},{"date":"2025-05-23","current":-10.577479,"twenty":-14.552086,"median":20.64237,"eighty":31.796884,"marketCap":244159956},{"date":"2025-05-30","current":-11.868448,"twenty":-14.483678,"median":20.515145,"eighty":31.510626,"marketCap":273959378},{"date":"2025-06-06","current":-11.250599,"twenty":-14.245514,"median":19.990339,"eighty":31.090781,"marketCap":259697570},{"date":"2025-06-13","current":-12.65393,"twenty":-13.898957,"median":19.083855,"eighty":30.976278,"marketCap":292090669},{"date":"2025-06-20","current":-9.82332,"twenty":-13.773118,"median":19.083855,"eighty":30.785439,"marketCap":226751689},{"date":"2025-06-27","current":-9.876005,"twenty":-13.751337,"median":19.083855,"eighty":30.680478,"marketCap":227967812},{"date":"2025-07-03","current":-11.552339,"twenty":-13.745115,"median":18.829404,"eighty":30.565975,"marketCap":266662639},{"date":"2025-07-11","current":-12.902986,"twenty":-13.143371,"median":-9.82332,"eighty":30.216104,"marketCap":297839615},{"date":"2025-07-18","current":-14.957693,"twenty":-13.611836,"median":-10.196903,"eighty":29.977556,"marketCap":345268417},{"date":"2025-07-25","current":-18.501942,"twenty":-13.979479,"median":-10.548775,"eighty":29.89804,"marketCap":427080338},{"date":"2025-08-01","current":-17.520089,"twenty":-14.593892,"median":-10.570486,"eighty":26.844623,"marketCap":404416225},{"date":"2025-08-08","current":-18.703103,"twenty":-14.909501,"median":-10.577479,"eighty":25.683689,"marketCap":431723718},{"date":"2025-08-15","current":-17.957373,"twenty":-15.155991,"median":-10.795594,"eighty":24.999851,"marketCap":509666156},{"date":"2025-08-22","current":-19.99406,"twenty":-15.421442,"median":-10.987175,"eighty":24.729496,"marketCap":567471411},{"date":"2025-08-29","current":-19.990163,"twenty":-15.528887,"median":-11.165181,"eighty":23.854819,"marketCap":567360814},{"date":"2025-09-05","current":-21.096831,"twenty":-16.235493,"median":-11.305678,"eighty":23.549477,"marketCap":598770263},{"date":"2025-09-12","current":-22.776317,"twenty":-17.271569,"median":-11.413443,"eighty":23.46678,"marketCap":646437419},{"date":"2025-09-19","current":-23.006223,"twenty":-17.715742,"median":-11.554734,"eighty":23.433384,"marketCap":652962621},{"date":"2025-09-26","current":-22.480166,"twenty":-18.057474,"median":-11.868448,"eighty":22.814749,"marketCap":638032073},{"date":"2025-10-03","current":-24.405145,"twenty":-18.52589,"median":-11.961844,"eighty":22.305846,"marketCap":692666818},{"date":"2025-10-10","current":-27.312096,"twenty":-18.938434,"median":-12.127082,"eighty":22.115008,"marketCap":775171919},{"date":"2025-10-17","current":-28.500595,"twenty":-19.602341,"median":-12.457671,"eighty":21.593382,"marketCap":808903898},{"date":"2025-10-24","current":-27.783599,"twenty":-20.103168,"median":-12.65393,"eighty":21.227608,"marketCap":788554114},{"date":"2025-10-31","current":-30.558062,"twenty":-20.870432,"median":-12.719639,"eighty":21.154454,"marketCap":867298929},{"date":"2025-11-07","current":-30.639894,"twenty":-21.250362,"median":-12.96286,"eighty":21.08766,"marketCap":869621458},{"date":"2025-11-14","current":-28.915921,"twenty":-22.006325,"median":-13.231068,"eighty":21.033589,"marketCap":952837445},{"date":"2025-11-21","current":-32.881534,"twenty":-22.215189,"median":-13.745115,"eighty":20.998602,"marketCap":1083512294},{"date":"2025-11-28","current":-36.922579,"twenty":-22.816843,"median":-13.778174,"eighty":20.973157,"marketCap":1216672807},{"date":"2025-12-05","current":-33.693335,"twenty":-23.242364,"median":-14.278382,"eighty":20.931809,"marketCap":1110262762},{"date":"2025-12-12","current":-34.763763,"twenty":-24.512694,"median":-14.593892,"eighty":20.769596,"marketCap":1145535502},{"date":"2025-12-19","current":-34.569792,"twenty":-27.267674,"median":-14.831115,"eighty":20.674177,"marketCap":1139143797},{"date":"2025-12-26","current":-38.014559,"twenty":-27.693195,"median":-14.933597,"eighty":20.674177,"marketCap":1252655736},{"date":"2026-01-02","current":-37.597882,"twenty":-28.489684,"median":-15.118842,"eighty":20.670996,"marketCap":1238925408},{"date":"2026-01-09","current":-34.979285,"twenty":-28.647112,"median":-15.258978,"eighty":20.655092,"marketCap":1152637396},{"date":"2026-01-16","current":-37.350031,"twenty":-29.232399,"median":-15.408801,"eighty":20.639189,"marketCap":1230758230},{"date":"2026-01-23","current":-33.075504,"twenty":-29.325414,"median":-15.443563,"eighty":20.626467,"marketCap":1089903999},{"date":"2026-01-30","current":-29.418807,"twenty":-29.517639,"median":-15.528887,"eighty":20.515145,"marketCap":969408531},{"date":"2026-02-06","current":-27.453961,"twenty":-29.48062,"median":-16.091391,"eighty":20.403822,"marketCap":904662930},{"date":"2026-02-13","current":-29.461912,"twenty":-29.48062,"median":-17.007828,"eighty":20.117564,"marketCap":970828909},{"date":"2026-02-20","current":-29.573265,"twenty":-29.488024,"median":-17.242297,"eighty":19.914003,"marketCap":974498221},{"date":"2026-02-27","current":-60.48704,"twenty":-29.707799,"median":-17.512905,"eighty":19.303319,"marketCap":1993168926},{"date":"2026-03-06","current":-55.02714,"twenty":-30.090518,"median":-17.81704,"eighty":19.099758,"marketCap":1813254325},{"date":"2026-03-13","current":-55.699943,"twenty":-30.574428,"median":-17.963839,"eighty":19.083855,"marketCap":1835424534},{"date":"2026-03-20","current":-46.447881,"twenty":-31.137829,"median":-18.431476,"eighty":19.083855,"marketCap":1530550575},{"date":"2026-03-27","current":-47.956591,"twenty":-32.06614,"median":-18.561811,"eighty":19.083855,"marketCap":1580265588},{"date":"2026-04-02","current":-41.305964,"twenty":-32.945472,"median":-18.707892,"eighty":19.083855,"marketCap":1723078270},{"date":"2026-04-10","current":-44.675498,"twenty":-33.393759,"median":-19.095844,"eighty":19.083855,"marketCap":1863638401},{"date":"2026-04-17","current":-42.609857,"twenty":-34.004406,"median":-19.561706,"eighty":18.969352,"marketCap":1777470174},{"date":"2026-04-24","current":-43.594639,"twenty":-34.788907,"median":-19.977117,"eighty":18.816681,"marketCap":1818550375},{"date":"2026-05-01","current":-44.030414,"twenty":-35.208457,"median":-20.266831,"eighty":18.756249,"marketCap":1836728722},{"date":"2026-05-08","current":-32.885673,"twenty":-35.663927,"median":-20.816267,"eighty":1.605963,"marketCap":1621165018},{"date":"2026-05-15","current":-34.614036,"twenty":-35.663927,"median":-21.021819,"eighty":-9.854931,"marketCap":1706368150},{"date":"2026-05-22","current":-33.726646,"twenty":-35.536117,"median":-21.24101,"eighty":-10.054175,"marketCap":1662622476},{"date":"2026-05-29","current":-33.709189,"twenty":-35.477208,"median":-21.439742,"eighty":-10.192113,"marketCap":1661761905},{"date":"2026-06-05","current":-33.406604,"twenty":-35.361812,"median":-22.020353,"eighty":-10.267821,"marketCap":1646845348},{"date":"2026-06-12","current":-30.951006,"twenty":-35.258528,"median":-22.098288,"eighty":-10.422477,"marketCap":1525791744},{"date":"2026-06-18","current":-32.769429,"twenty":-35.21133,"median":-22.480166,"eighty":-10.551201,"marketCap":1615434519},{"date":"2026-06-26","current":-39.627064,"twenty":-35.273781,"median":-22.826974,"eighty":-10.561865,"marketCap":1953495352},{"date":"2026-07-02","current":-40.226416,"twenty":-35.557603,"median":-22.973101,"eighty":-10.565696,"marketCap":1983041611},{"date":"2026-07-10","current":-43.944726,"twenty":-36.020976,"median":-23.275097,"eighty":-10.575275,"marketCap":2166343157},{"date":"2026-07-17","current":-42.993327,"twenty":-36.290379,"median":-24.416835,"eighty":-10.577479,"marketCap":2119442057},{"date":"2026-07-24","current":-41.665152,"twenty":-36.922579,"median":-25.632611,"eighty":-10.577479,"marketCap":2053966975},{"date":"2026-07-31","current":-43.697421,"twenty":-37.223591,"median":-27.238059,"eighty":-10.749704,"marketCap":2154151740},{"date":"2026-08-07","current":-36.182159,"twenty":-37.223591,"median":-27.449273,"eighty":-10.795027,"marketCap":2232294496},{"date":"2026-08-14","current":-36.560492,"twenty":-37.14313,"median":-27.55759,"eighty":-10.795594,"marketCap":2255636115},{"date":"2026-08-21","current":-33.297956,"twenty":-36.964247,"median":-27.969419,"eighty":-10.845405,"marketCap":2054350670},{"date":"2026-08-28","current":-35.107881,"twenty":-36.922579,"median":-28.427404,"eighty":-10.961312,"marketCap":2166015824},{"date":"2026-09-04","current":-36.30827,"twenty":-36.860843,"median":-28.502544,"eighty":-11.000041,"marketCap":2240075036},{"date":"2026-09-11","current":-35.121893,"twenty":-36.771144,"median":-28.581687,"eighty":-11.069277,"marketCap":2166880328},{"date":"2026-09-16","current":-35.31573,"twenty":-36.696967,"median":-28.640877,"eighty":-11.134046,"marketCap":2178839306}],"updateTime":1789639766282},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PVLA\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1102714475","title":"Palvella Therapeutics任命全國知名兒科皮膚科專家James R. Treat博士為首席醫療官","url":"https://stock-news.laohu8.com/highlight/detail?id=1102714475","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102714475?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 19:32","pubTimestamp":1788953534,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics宣布，任命在美国颇具声望的儿科皮肤科专家James R. Treat博士出任首席医疗官一职。作为全国公认的儿科皮肤科权威，他在罕见皮肤病诊疗领域拥有卓越建树，有望为Palvella的在研管线注入新的学术动力与临床洞察。Palvella Therapeutics是一家专注于罕见皮肤病创新疗法开发的临床阶段生物制药公司，此次引入重量级医学人才，再次彰显了公司构建高水平临床团队、加速核心产品管线的坚定决心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197527612","title":"Palvella Therapeutics完成向FDA滾動提交Qtorin™雷帕黴素新藥申請，用於治療微囊性淋巴管畸形","url":"https://stock-news.laohu8.com/highlight/detail?id=1197527612","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197527612?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 19:31","pubTimestamp":1788175870,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics宣布，已圆满完成向美国食品药品监督管理局（FDA）滚动提交Qtorin™雷帕霉素的新药申请（NDA）。该药物旨在针对微囊性淋巴管畸形这一罕见病症提供治疗方案。\n此次提交标志着该公司在推进这一潜在疗法走向临床应用的进程中，迈出了关键性的一步。Qtorin™作为一种新型雷帕霉素制剂，其开发聚焦于满足微囊性淋巴管畸形患者群体中尚未被满足的医疗需求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188021390","title":"Palvella Therapeutics加速美國上市籌備，Qtorin雷帕黴素若獲批有望於2027年上半年啓動","url":"https://stock-news.laohu8.com/highlight/detail?id=1188021390","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188021390?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 19:31","pubTimestamp":1788175869,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics正全力推进美国市场的上市前准备工作，为旗下产品Qtorin雷帕霉素可能于2027年上半年获批上市铺平道路——前提是最终获得监管机构的批准。该公司目前正密集开展各项筹备工作，以应对潜在的市场准入需求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142355864","title":"Palvella Therapeutics任命罕見病生物技術資深高管兼商業領袖Matt Pauls加入董事會","url":"https://stock-news.laohu8.com/highlight/detail?id=1142355864","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142355864?lang=zh_tw&edition=fundamental","pubTime":"2026-06-30 19:32","pubTimestamp":1782819120,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics宣布，任命在罕见病生物技术领域成就卓著且拥有丰富商业领导经验的高管Matt Pauls加入其董事会。Pauls先生持有法学博士学位及工商管理硕士学位，他的加入将为公司带来战略与商业运营方面的专业见解。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158097855","title":"Palvella Therapeutics向FDA滾動提交Qtorin™雷帕黴素治療微囊型淋巴管畸形新藥申請的首個模塊","url":"https://stock-news.laohu8.com/highlight/detail?id=1158097855","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158097855?lang=zh_tw&edition=fundamental","pubTime":"2026-06-29 19:30","pubTimestamp":1782732648,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics公司已向美国食品药品监督管理局（FDA）滚动提交了其用于治疗微囊型淋巴管畸形的在研药物Qtorin™雷帕霉素新药申请（NDA）的首个模块。此举标志着该药物正式进入监管审批的关键阶段。滚动提交允许公司在完成所有申请模块前分阶段递交材料，旨在加速整体审评流程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146242398","title":"FDA批准對Palvella公司Qtorin™雷帕黴素新藥申請進行滾動審評，用於治療微囊性淋巴管畸形","url":"https://stock-news.laohu8.com/highlight/detail?id=1146242398","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146242398?lang=zh_tw&edition=fundamental","pubTime":"2026-06-22 19:31","pubTimestamp":1782127866,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已同意对Palvella Therapeutics公司旗下产品Qtorin™雷帕霉素的新药申请（NDA）启动滚动审评程序，该药物旨在治疗微囊性淋巴管畸形。\n这一决定意味着Palvella公司可以分阶段提交NDA的相关模块，而无需等待所有资料完全齐备，从而有望加速整体的审评流程。Qtorin™雷帕霉素是一种针对罕见病微囊性淋巴管畸形开发的局部治疗药物。\n获得滚动审评资格通常表明监管机构认为该药物针对的疾病领域存在未满足的医疗需求，并且初步提交的临床数据展现了积极的潜力。此举为Palvella公司推进该候选药物的上市进程提供了重要助力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139686968","title":"Palvella Therapeutics宣佈完成Qtorin™雷帕黴素治療微囊型淋巴管畸形的新藥申請前會議","url":"https://stock-news.laohu8.com/highlight/detail?id=1139686968","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139686968?lang=zh_tw&edition=fundamental","pubTime":"2026-06-03 19:30","pubTimestamp":1780486224,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics宣布，已成功完成与美国食品药品监督管理局（FDA）就Qtorin™雷帕霉素用于治疗微囊型淋巴管畸形（Microcystic Lymphatic Malformations）的新药申请前会议。此次会议是该公司推进该候选药物研发进程中的一个重要里程碑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103509440","title":"Palvella Therapeutics公布Qtorin™ Rapamycin治療皮膚靜脈畸形II期Toiva試驗新數據，亮相第83屆皮膚病研究學會年會","url":"https://stock-news.laohu8.com/highlight/detail?id=1103509440","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103509440?lang=zh_tw&edition=fundamental","pubTime":"2026-05-15 19:33","pubTimestamp":1778844792,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics公司宣布，其用于治疗皮肤静脉畸形的Qtorin™ Rapamycin在II期Toiva临床试验中取得的最新数据，已于第83届皮肤病研究学会年会上公布。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129505162","title":"Palvella Therapeutics宣佈首位患者接受快速通道藥物Qtorin™雷帕黴素治療臨床顯著性血管角化瘤的二期Lotu試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=1129505162","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1129505162?lang=zh_tw&edition=fundamental","pubTime":"2026-05-04 19:32","pubTimestamp":1777894342,"startTime":"0","endTime":"0","summary":"生物制药公司Palvella Therapeutics（股票代码：PVLA）迎来重要研发里程碑——其获得快速通道认定的创新药Qtorin™雷帕霉素，已正式启动针对临床显著性血管角化瘤的二期Lotu临床试验，并完成首位患者给药。该突破性进展标志着公司在罕见皮肤病治疗领域迈出关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101160402","title":"Palvella Therapeutics任命罕見皮膚病領域權威皮膚科醫生John D. Doux博士加入董事會","url":"https://stock-news.laohu8.com/highlight/detail?id=1101160402","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101160402?lang=zh_tw&edition=fundamental","pubTime":"2026-04-13 19:34","pubTimestamp":1776080044,"startTime":"0","endTime":"0","summary":"生物制药公司Palvella Therapeutics近日宣布，正式任命约翰·D·杜克斯医学博士、工商管理硕士加入其董事会。杜克斯博士是皮肤医学领域的资深专家，尤其在罕见皮肤疾病的研究与临床治疗方面享有盛誉。此次人事变动将为公司带来宝贵的专业见解和行业领导力，进一步强化其在罕见皮肤病治疗领域的战略布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139195793","title":"異動解讀 | Palvella Therapeutics新藥申請進展順利，盤中大漲9.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=1139195793","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139195793?lang=zh_tw&edition=fundamental","pubTime":"2026-03-31 21:40","pubTimestamp":1774964431,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics(PVLA)今日盘中大涨9.42%，引起了市场的广泛关注。消息面上，生物制药公司Palvella Therapeutics宣布，其针对微囊性淋巴管畸形的在研药物Qtorin Rapamycin的新药申请正稳步推进，预计将按原定计划于2026年下半年提交监管机构。该时间表标志着公司在推进该创新疗法上市进程中迈出关键一步，增强了投资者对公司研发管线进展和未来商业化前景的信心。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162347775","title":"Palvella公司Qtorin Rapamycin治療微囊性淋巴管畸形的新藥申請按計劃將於2026年下半年提交","url":"https://stock-news.laohu8.com/highlight/detail?id=1162347775","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162347775?lang=zh_tw&edition=fundamental","pubTime":"2026-03-31 19:33","pubTimestamp":1774956825,"startTime":"0","endTime":"0","summary":"生物制药公司Palvella Therapeutics宣布，其针对微囊性淋巴管畸形的在研药物Qtorin Rapamycin的新药申请正稳步推进，预计将按原定计划于2026年下半年提交监管机构。该时间表标志着公司在推进该创新疗法上市进程中迈出关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111986483","title":"Palvella Therapeutics將於2026年3月31日召開2025財年全年業績電話會議並公布公司最新進展","url":"https://stock-news.laohu8.com/highlight/detail?id=1111986483","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111986483?lang=zh_tw&edition=fundamental","pubTime":"2026-03-24 19:30","pubTimestamp":1774351813,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics宣布，计划于2026年3月31日举行2025财年全年财务业绩电话会议。此次会议将详细披露公司全年财务表现，并就业务运营、研发管线及战略规划提供最新动态。\n投资者及公众可通过指定渠道接入会议，与管理层直接交流，深入了解公司发展近况与未来展望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129093196","title":"Palvella Therapeutics任命罕見病商業領袖Jennifer J. Mcdonough為市場準入與患者服務高級副總裁，強化領導團隊","url":"https://stock-news.laohu8.com/highlight/detail?id=1129093196","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1129093196?lang=zh_tw&edition=fundamental","pubTime":"2026-03-23 19:35","pubTimestamp":1774265729,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics宣布了一项重要人事任命，罕见病领域的商业领袖Jennifer J. Mcdonough已加入公司，担任市场准入与患者服务高级副总裁。这一举措旨在加强公司的领导团队实力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KRYS","PVLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":14,"code":"91000000","status":"200"}]}}